Page 5 - Randomized Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update

Arcus and Gilead announced an additional equity investment of $320 million into Arcus and modifications to their domvanalimab + zimberelimab clinical program to focus on the highest unmet medical.

Terry rosenJohanna mercierDevelopment rd expensesExchange commission onExchange commissionCompany annual report on formArcus biosciences incArcus biosciencesChief commercial officerDomvanalimab zimberelimab milestonesSafety dataOverall survivalSynthetic control armFourth quarterFull yearCash equivalents

Ibrutinib Combined With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results From the Randomized Phase 3 SYMPATICO Study

Michael Wang, MD, presents the primary analysis results from the multinational, randomized, double-blind, phase 3 SYMPATICO study comparing ibrutinib plus venetoclax vs ibrutinib plus placebo in patients with relapsed/refractory mantle cell lymphoma (R/R MCL).

Ibrutinib combined with venetoclaxPatients withRefractory mantle cell lymphomaPrimary analysis results fromRandomized phaseMantle cell lymphomaRr mclRelapsed refractory mantle cell lymphoma

First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK s Allogeneic INKT Cell Therapy and Agenus Botensilimab and…

Trial is Supported by Stand Up To Cancer as Part of an Initiative to Find Treatments for the ~70% of Gastroesophageal Cancer (GEC) Patients for Whom Current…

Initiative to find treatmentsStand up to cancerFind treatmentsGastroesophageal cancerWhom current treatments don tRandomized phaseFirst novel combinationAllogeneic cell therapyReaking news

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesJulian peiRobert kimDavid kirnArshadm khananiKatherine smithProgram updatesClinic research at sierra eye associatesCorporate communicationsEuropean unionClinical data programExchange commissionPositive interim dataRandomized phaseFavorable tolerabilityClinical activity

4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden

Initial interim landmark data analysis will be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial at Angiogenesis, Exudation, and Degeneration 2024.

United statesKatherine smithJulian peiArshadm khananiReno school of medicineClinical associate professor at university of nevadaClinical research at sierra eye associatesClinical data programCorporate communicationsPrincipal investigatorMolecular therapeuticsWebcast detailsTreatment burdenInterim clinical dataDegeneration presentation detailsInterim results